Este articulo es un Preprint
Los preprints son informes de investigación preliminares que no han sido certificados por revisión por pares. No deben considerarse para guiar la práctica clínica o los comportamientos relacionados con la salud y no deben publicarse en los medios como información establecida.
Los preprints publicados en línea permiten a los autores recibir comentarios rápidamente, y toda la comunidad científica puede evaluar de forma independiente el trabajo y responder adecuadamente. Estos comentarios se publican junto con los preprints para que cualquiera pueda leer y servir como una revisión pospublicación.
COVID-19 Impact in Crohn Disease Patients Underwent Autologous Hematopoietic Stem Cell Transplantation (preprint)
medrxiv; 2023.
Preprint
en Inglés
| medRxiv | ID: ppzbmed-10.1101.2023.06.22.23291610
ABSTRACT
SARS COV 2 is the virus responsible for COVID-19, a disease that has been blamed for inducing or exacerbating symptoms in patients with autoimmune diseases. Crohn's disease (CD) is an inflammatory bowel disease that affects genetically susceptible patients who develop an abnormal mucosal immune response to the intestinal microbiota. Patients who underwent Hematopoietic Stem cell Transplantation are considered at risk for COVID-19. The objective of this report was to describe for the first time the impact of COVID-19 in a group of 50 patients with Crohn's Disease (CD, 28 females, and 22 male) with a mean age of 38 years, previously submitted to Autologous, non-myeloablative, Hematopoietic Stem Cell Transplantation (Auto HSCT) between 2013 and 2021. In this series, 19 patients were diagnosed with positive COVID-19. In two (2) patients there was a report of the occurrence of two infectious episodes. Parameters related to HSCT, such as time elapsed since the procedure, vaccination status, CD status before and after infection, and clinical manifestations resulting from COVID-19, were evaluated. Among the patients with COVID-19, in three, submitted to Auto HSCT less than six (6) months ago, there was a change in the CD status, and one of them, in addition to the CD symptoms, started to present thyroid impairment with positive anti-TPO. Only one of the patients required hospitalization for five days to treat COVID-19 and remained in CD clinical remission. Nine patients reported late symptoms that may be related to COVID-19. There were no deaths, and the statistical evaluation of the series of COVID-19 patients after HSCT and those who did not present an infectious episode did not present significant data regarding the analyzed parameters. Despite the change in CD status in three patients and the presence of nine patients with late symptoms, we can conclude that there was no significant adverse impact concerning COVID-19 in the evaluated patients who underwent HSCT to treat CD. Key Words Inflammatory bowel disease, Crohn Disease, SARs COV 2, COVID - 19, Autologous Hematopoietic Stem Cell Transplantation, Stem Cell Therapy.
Texto completo:
Disponible
Colección:
Preprints
Base de datos:
medRxiv
Asunto principal:
Enfermedades Autoinmunes
/
Tiroiditis
/
Enfermedades Inflamatorias del Intestino
/
Enfermedad de Crohn
/
COVID-19
Idioma:
Inglés
Año:
2023
Tipo del documento:
Preprint
Similares
MEDLINE
...
LILACS
LIS